Malvern Instruments CTO will Discuss New Technology for Characterizing Protein Formulations at International BioAnalytical Congress
Dr E. Neil Lewis, Chief Technology Officer at Malvern Instruments and Head of the company’s Bioscience Development Initiative, will speak at the International BioAnalytical Congress taking place in Berlin (Germany) on 11 and 12 September 2013.
The theme of the conference is the future of bioanalytical development and Dr Lewis will discuss ‘Advances in the integrated measurements of higher order proteins’, focusing especially on new technology that combines dynamic light scattering with Raman spectroscopy. He will examine this as a means of providing structural, thermodynamic and kinetic insights into mechanisms of protein aggregation and the factors that influence protein stability. Malvern is pleased also to be a sponsor and exhibitor at the Congress.
Determining the ease with which a protein therapeutic can be developed, formulated and manufactured requires non-invasive, non-destructive measurement of numerous physicochemical properties, including viscosity, protein structure and hydrodynamic size. Malvern offers a growing portfolio of analytical technologies focused on the needs of biopharmaceutical developers, including:
The new Viscosizer 200 which automates low volume viscosity measurement and size analysis. It is ideally placed to serve those working within biopharmaceutical preformulation and formulation development who need rapid viscosity information on a large number of low volume samples, in order to assess candidate developability.
Archimedes, which uses the technique of resonant mass measurement to detect and count particles in the size range 50 nm–5 µm. It is especially useful for characterising protein aggregates in formulation or buffer.
The Zetasizer Nano ZSP for the measurement of size, electrophoretic mobility of proteins, zeta potential of nanoparticles and surfaces, and optionally the microrheology of protein and polymer solutions. Protein mobility is one property that has been identified as a promising indicator of formulation stability, viscosity, and behavior.
Viscotek SEC-MALS 20 extends Malvern’s family of light scattering detectors for measuring the absolute molecular weight of proteins, macromolecules and polymers. Static light scattering is widely used within gel permeation/size exclusion chromatography (GPC/SEC) for the determination of the absolute molecular weight of protein, polymer and macromolecular species without the need for external, potentially inaccurate calibrations.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...